Data Sheet 1_Therapeutic advances in eculizumab for atypical hemolytic uremic syndrome: a

A narrative review of medical literature on eculizumab treatment for atypical hemolytic uremic syndrome (aHUS). The document integrates evidence from clinical trials, observational cohorts, and registry analyses up to 2025. It was authored by Dandan Zhang and published on figshare under a CC-BY-4.0 license.

Use Cases

• Reviewing evidence on eculizumab dosing strategies based on the discussion of dose optimization.
• Assessing the feasibility of treatment discontinuation based on the analysis of relapse risk and monitoring strategies.
• Comparing therapeutic approaches for specific aHUS subtypes based on the discussion of tailored management.
• Identifying future research directions for C5 inhibition based on the outlined future directions.

Strengths

• The review is based on a PubMed literature search conducted through 2025, providing a recent synthesis.
• It integrates evidence from multiple study types: clinical trials, observational cohorts, and registry-based analyses.

Limitations

• The dataset is a single 51.7 KB DOCX file, indicating a limited scope of data.
• Row count and column-level documentation are absent; field semantics must be inferred from the text.
• The data is a review article, not a primary dataset of patient records or clinical measurements.

Provenance

Source

figshare

Collection Method

Literature review based on PubMed search.

Time Range

Literature reviewed through 2025.

Freshness

Last updated 2026-05-28 05:30:14